FRAX and its applications to clinical practice.

[1]  O. Johnell,et al.  At what hip fracture risk is it cost-effective to treat? , 2006, Osteoporosis International.

[2]  C. Cooper,et al.  Guidelines for diagnosis and management of osteoporosis , 2005, Osteoporosis International.

[3]  R. Eastell,et al.  The Use of Biochemical Markers of Bone Turnover in Osteoporosis , 2000, Osteoporosis International.

[4]  J. Kanis,et al.  The cost-effectiveness of risedronate in the UK for the management of osteoporosis using the FRAX® , 2010, Osteoporosis International.

[5]  O Johnell,et al.  Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. , 1996, BMJ.

[6]  L. Melton,et al.  Cost-effective osteoporosis treatment thresholds: the United States perspective , 2008, Osteoporosis International.

[7]  J. Pfeilschifter,et al.  [Diagnosis and treatment of postmenopausal osteoporosis and osteoporosis in men. German Guidelines Update 2006]. , 2007, Der Orthopade.

[8]  C. Cooper,et al.  Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. , 2000, Rheumatology.

[9]  W. Gerth,et al.  Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge? , 2004, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[10]  Mark Stevenson,et al.  Glucocorticoid-induced osteoporosis: a systematic review and cost-utility analysis. , 2007, Health technology assessment.

[11]  B. O'brien,et al.  Challenges for Model-Based Economic Evaluations of Postmenopausal Osteoporosis Interventions , 2001, Osteoporosis International.

[12]  J. Kanis,et al.  Economic Evaluation of Interventions for Osteoporosis , 2002, Osteoporosis International.

[13]  J A Kanis,et al.  Treatment of established osteoporosis: a systematic review and cost-utility analysis. , 2002, Health technology assessment.

[14]  Claus Christiansen,et al.  Efficacy of Bazedoxifene in Reducing New Vertebral Fracture Risk in Postmenopausal Women With Osteoporosis: Results From a 3‐Year, Randomized, Placebo‐, and Active‐Controlled Clinical Trial , 2008, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[15]  P. Delmas,et al.  Assessment of 10-year absolute fracture risk: a new paradigm with worldwide application , 2008, Osteoporosis International.

[16]  C. Glüer,et al.  Quantitative Ultrasound Techniques for the Assessment of Osteoporosis: Expert Agreement on Current Status , 1997, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[17]  R. Rizzoli,et al.  Remaining lifetime and absolute 10-year probabilities of osteoporotic fracture in Swiss men and women , 2009, Osteoporosis International.

[18]  C. Cooper,et al.  The cost-effectiveness of alendronate in the management of osteoporosis. , 2008, Bone.

[19]  H. Genant,et al.  Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial. , 2003, Bone.

[20]  J. Kanis,et al.  Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX. , 2009, Bone.

[21]  A. Kurth,et al.  Diagnostik und Therapie der postmenopausalen Osteoporose und der Osteoporose des Mannes , 2007, Der Orthopäde.

[22]  C. Slemenda,et al.  Age and bone mass as predictors of fracture in a prospective study. , 1988, The Journal of clinical investigation.

[23]  H. Kroger,et al.  Smoking and fracture risk: a meta-analysis , 2005, Osteoporosis International.

[24]  S. Papapoulos,et al.  A New Approach to the Development of Assessment Guidelines for Osteoporosis , 2002, Osteoporosis International.

[25]  J. Osieleniec,et al.  Current understanding of osteoporosis according to the position of the World Health Organization (WHO) and International Osteoporosis Foundation. , 2007, Ortopedia, traumatologia, rehabilitacja.

[26]  Olof Johnell,et al.  Alcohol intake as a risk factor for fracture , 2005, Osteoporosis International.

[27]  M. Fukunaga,et al.  Diagnostic criteria of primary osteoporosis , 1998, Journal of Bone and Mineral Metabolism.

[28]  O. Johnell,et al.  FRAX™ and the assessment of fracture probability in men and women from the UK , 2008, Osteoporosis International.

[29]  L. Melton,et al.  Implications of absolute fracture risk assessment for osteoporosis practice guidelines in the USA , 2008, Osteoporosis International.

[30]  O. Johnell,et al.  Requirements for DXA for the management of osteoporosis in Europe , 2005, Osteoporosis International.

[31]  J. Kanis,et al.  Diagnosis of osteoporosis and assessment of fracture risk , 2002, The Lancet.

[32]  O. Johnell,et al.  BMD, clinical risk factors and their combination for hip fracture prevention , 2009, Osteoporosis International.

[33]  Niklas Zethraeus,et al.  Intervention thresholds for osteoporosis in the UK. , 2005, Bone.

[34]  H. Wahner,et al.  Updated Data on Proximal Femur Bone Mineral Levels of US Adults , 1998, Osteoporosis International.

[35]  H. K. Genant,et al.  Advanced CT bone imaging in osteoporosis , 2008, Rheumatology.

[36]  O. Johnell,et al.  The impact of the use of multiple risk indicators for fracture on case-finding strategies: a mathematical approach , 2005, Osteoporosis International.

[37]  G. Guyatt,et al.  Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women. , 2002, Endocrine reviews.

[38]  Mark Lunt,et al.  Characteristics of a prevalent vertebral deformity predict subsequent vertebral fracture: results from the European Prospective Osteoporosis Study (EPOS). , 2003, Bone.

[39]  Olof Johnell,et al.  A Meta‐Analysis of Prior Corticosteroid Use and Fracture Risk , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[40]  O. Johnell,et al.  Optimization of BMD Measurements to Identify High Risk Groups for Treatment—A Test Analysis , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[41]  M. Allende-Vigo.  The use of biochemical markers of bone turnover in osteoporosis. , 2007, Puerto Rico health sciences journal.

[42]  O. Johnell,et al.  Intervention thresholds for osteoporosis in men and women: a study based on data from Sweden , 2004, Osteoporosis International.

[43]  J Bamford,et al.  Current practice, accuracy, effectiveness and cost-effectiveness of the school entry hearing screen. , 2007, Health technology assessment.

[44]  L. Melton,et al.  A reference standard for the description of osteoporosis. , 2008, Bone.

[45]  D J Baylink,et al.  Glucocorticoid-induced osteoporosis. , 1983, The New England journal of medicine.

[46]  O. Johnell,et al.  Ten Year Probabilities of Osteoporotic Fractures According to BMD and Diagnostic Thresholds , 2001, Osteoporosis International.

[47]  G. Guyatt,et al.  Meta-Analyses of Therapies for Postmenopausal Osteoporosis , 2002 .

[48]  Jacques P. Brown,et al.  Recommendations for bone mineral density reporting in Canada: a shift to absolute fracture risk assessment. , 2007, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

[49]  H. Johansson,et al.  Ten-year fracture probability in Hong Kong Southern Chinese according to age and BMD femoral neck T-scores , 2009, Osteoporosis International.

[50]  O. Johnell,et al.  International Variations in Hip Fracture Probabilities: Implications for Risk Assessment , 2002, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[51]  H. Johansson,et al.  Development and application of a Japanese model of the WHO fracture risk assessment tool (FRAX™) , 2008, Osteoporosis International.

[52]  Jacques P. Brown,et al.  The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women , 2007, Osteoporosis International.

[53]  O. Johnell,et al.  The Burden of Osteoporotic Fractures: A Method for Setting Intervention Thresholds , 2001, Osteoporosis International.

[54]  J. Kanis,et al.  Case finding for the management of osteoporosis with FRAX®—assessment and intervention thresholds for the UK , 2008, Osteoporosis International.